Cardiotoxicities of Modern Treatments in Breast Cancer
- 91 Downloads
Purpose of review
This paper will focus on novel breast cancer therapies used in clinical practice today, as well as review our understanding of standard therapies and their potential impact on cardiovascular health.
Established and novel treatments such as anthracyclines, HER2-targeted agents, and immunotherapy have contributed to improvements in breast cancer outcomes; however, these treatments may be associated with an increased risk of cardiovascular injury. The number of available breast cancer treatments continues to expand, as does the need for health care providers to understand the potential impact of these treatments on cardiovascular health.
Collaborative approaches in the development of risk stratification, prevention, and surveillance strategies for patients exposed to established and novel breast cancer treatments will facilitate improvements in patient outcomes without compromising their cardiovascular health.
KeywordsBreast cancer Novel treatments Cardiac injury
The authors would like to thank Erin Campbell, MS, for her editorial contributions to this manuscript.
Compliance with Ethical Standards
Conflict of Interest
Susan Dent has received honorarium from Novartis, Pfizer and Hoffman La-Roche. Chiara Melloni receives support for research from the NICHD (HHSN27500027, HHSN27500043). All industry disclosures are available at: www.dcri.org/about-us/conflict-of-interest/. Josee Ivars declares no potential conflicts of interest. Sarah Sammons reports a grant from Astra Zeneca. Gretchen Kimmick is on the scientific advisory boards of Boehringer Ingelheim, Eisai, Genomic Health and Agendia. Dr. Kimmick is a consultant for AstraZeneca, Novartis, and Pfizer and has received research funding from Bionovo, PUMA, and Roche.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. editors. GLOBOCAN 2012: Estimated cancer incidence, mortality, and prevalence worldwide in 2012 v1.0. World Health Organization International Agency for Research on Cancer web site. http://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012. Accessed March 28, 2019.
- 2.American Cancer Society. Cancer facts and figures 2016. American Cancer Society web site. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2016/cancer-facts-and-figures-2016.pdf. Accessed March 28, 2019.
- 19.Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671–80.CrossRefGoogle Scholar
- 20.Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol. 2017;35(8):870–7.CrossRefGoogle Scholar
- 22.Munster P, Krop IE, LoRusso P, Ma C, Siegel BA, Shields AF, et al. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. Br J Cancer. 2018;119(9):1086–93.CrossRefGoogle Scholar
- 24.•• Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, et al. Anthracycline-induced cardiotoxicity: a multicenter randomized trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial. Eur J Cancer. 2018;94:126–37. Low cumulative doses of anthracyclines in adult cancer patients, with low cardiovascular risk, resulted in increases in troponin levels in approximately 25% of all patients. No difference in cardiotoxicity between two different prevention strategies comparing upfront enalapril vs troponin-triggered enalapril.CrossRefGoogle Scholar
- 26.Huang DT, Angus DC, Chang CH, Doi Y, Fine MJ, Kellum JA, et al. Design and rationale of the Procalcitonin Antibiotic Consensus Trial (ProACT), a multicenter randomized trial of procalcitonin antibiotic guidance in lower respiratory tract infection. BMC Emerg Med. 2017;17(1):25.CrossRefGoogle Scholar
- 27.The University of Edinburgh. The Cardiac CARE Trial – can we prevent heart muscle injury related to chemotherapy? The University of Edinburgh web site. https://www.ed.ac.uk/usher/edinburgh-clinical-trials/our-studies/ukcrc-studies/cardiac-care/cardiac-care-trial. Published January 16, 2019. Accessed March 21, 2019.
- 32.U.S. Food & Drug Administration. Drug approvals and databases. U.S. Food & Drug Administration web site. https://www.fda.gov/Drugs/InformationOnDrugs/. Updated November 1, 2018. Accessed March 29, 2019.
- 35.de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomized, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014;15(10):1137–46.CrossRefGoogle Scholar
- 36.Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomized trial. Lancet Oncol. 2016;17(6):791–800.CrossRefGoogle Scholar
- 38.• Van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomized, phase 3 trial. Lancet Oncol. 2018;19(12):1630–40. In HER 2+ early breast cancer, when using dual HER2 blockade, anthracyclines can be avoided from the chemotherapy regimen, without compromising pathological complete response rates.CrossRefGoogle Scholar
- 40.Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Investig New Drugs. 2014;32(5):825–37.CrossRefGoogle Scholar
- 46.Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomized controlled trial. Lancet Oncol. 2016;17(4):425–39.CrossRefGoogle Scholar
- 47.Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541–7.PubMedGoogle Scholar
- 49.Novartis Pharmaceuticals Corporation. LABEL: KISQALI- ribociclib tablet, film coated. Drug label information. DailyMed web site. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8. Updated November 3, 2018. Accessed March 28, 2019.
- 51.CredibleMeds®. CredibleMeds web site. www.crediblemeds.org. Accessed March 29, 2019.
- 57.Zeichner S, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer (Auckl). 2016;10:25–36.Google Scholar
- 60.Olaparib In Metastatic Breast Cancer. ClinicalTrials.gov web site. https://clinicaltrials.gov/ct2/show/NCT03344965?term=olaparib&draw=2&rank=11. Updated February 18, 2019. Accessed March 28, 2019.
- 62.Olaparib + Sapacitabine in BRCA Mutant Breast Cancer. ClinicalTrials.gov web site. https://clinicaltrials.gov/ct2/show/NCT03641755?term=olaparib&draw=4&rank=31. Updated October 2, 2018. Accessed March 28, 2019.
- 66.•• Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–21. Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with PD-L1–positive tumors, proving efficacy of immunotherapy in this subset of patients. PD-L1 expression status on tumor-infiltrating immune cells should be taken into consideration when considering treatment choices for metastatic triple-negative breast cancer.CrossRefGoogle Scholar